X0407 4 2023-05-08 0 0001484565 SOLENO THERAPEUTICS INC SLNO 0001422484 Mackaness James H 203 REDWOOD SHORES PKWY, STE 500 REDWOOD CITY CA 94065 0 1 0 0 Chief Financial Officer 0 Warrants (right to buy) 1.75 2023-05-08 4 A 0 2143 0.4425 A 2023-05-08 Common Stock 2143 2143 D Warrants (right to buy) 2.50 2023-05-08 4 A 0 3500 0.4425 A 2023-05-08 Common Stock 3500 3500 D The Warrants were acquired pursuant to a Securities Purchase Agreement, dated December 16, 2022, between the Issuer and certain entities and members of the Issuer's management team. The acquisition was approved by the Issuer's Board of Directors and constitutes an exempt acquisition under Rule 16b-3(d)(1) of the Securities Exchange Act of 1934, as amended. The Warrants will expire upon the earlier of (i) 30 days following announcement of positive top-line data from the randomized withdrawal period of Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS), or (ii) November 8, 2026. The Warrants will expire upon the earlier of (i) 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS or (ii) November 8, 2026. /s/ James Mackaness 2023-05-10